<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093468</url>
  </required_header>
  <id_info>
    <org_study_id>MST-188-07</org_study_id>
    <nct_id>NCT02093468</nct_id>
  </id_info>
  <brief_title>Evaluation of MST-188 in Acute Lower Limb Ischemia</brief_title>
  <official_title>Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy of MST-188 in Subjects With Acute Lower Limb Ischemia Receiving Catheter-Directed Recombinant Tissue Plasminogen Activator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of MST-188 in subjects&#xD;
      receiving catheter-directed rt-PA for acute lower limb ischemia and to evaluate whether&#xD;
      treatment with MST-188 results in more rapid thrombolysis of the occlusion and more rapid&#xD;
      tissue perfusion in the effected blood vessel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Program discontinued to persue alternate indications.&#xD;
  </why_stopped>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic assessment of the change in the volume of thrombus (Exploratory endpoint)</measure>
    <time_frame>Baseline, 8 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in TcPO2 (Exploratory endpoint)</measure>
    <time_frame>Baseline, 8, 12, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Randomization through 30 days post-treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acute Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administered IV for 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MST-188</intervention_name>
    <arm_group_label>Higher Dose</arm_group_label>
    <arm_group_label>Lower Dose</arm_group_label>
    <other_name>vepoloxamer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥30 to &lt;80&#xD;
&#xD;
          -  Symptoms consistent with ALI in target lower limb classified as Rutherford Category&#xD;
             IIa or IIb&#xD;
&#xD;
          -  Subject is hospitalized or in the process of hospitalization for the treatment of ALI&#xD;
&#xD;
          -  Angiographic confirmation of thrombotic lower limb arterial occlusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prosthetic bypass graft occlusion within 1 month of implantation or autogenous graft&#xD;
             occlusion within 6 months of placement&#xD;
&#xD;
          -  Treatment with a thrombolytic agent within the last 48 hours&#xD;
&#xD;
          -  Subject's laboratory results indicate inadequate organ function&#xD;
&#xD;
          -  NYHA Class IV congestive heart failure&#xD;
&#xD;
          -  Prior major amputation of the target limb&#xD;
&#xD;
          -  Other complications or contraindications for receiving rt-PA, anticoagulants, or&#xD;
             contrast media&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin L Parsley, D.O.</last_name>
    <role>Study Director</role>
    <affiliation>Mast Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute limb ischemia</keyword>
  <keyword>ALI</keyword>
  <keyword>Acute lower extremity arterial occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

